NR3C2 and chronic kidney disease: Finerenone, an innovative selective non-steroidal MR antagonist, showed remarkable safety and efficacy in the FIDELIO-DKD and FIGARO-DKD trials in reducing both renal and cardiovascular complications in patients with type 2 diabetes and CKD [87,88].